Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous Perampanel as a Substitute for Oral Perampanel in Epilepsy
jRCT2080224165Phase 2Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Nov 2018
- Modality
- Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of perampanel in Focal Onset Epilepsy, epilepsy and Epilepsy with generalized tonic-clonic seizures alone, sponsored by Eisai Co., Ltd. Primary endpoint: Safety and tolerability of intravenous perampanel. Started Nov 2018; status: completed.
02
Drugs
perampanel
03
Conditions
Focal Onset EpilepsyepilepsyEpilepsy with generalized tonic-clonic seizures alone
Beyond the preview
Go deeper on jRCT2080224165.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224165.